Standout Papers

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults 2023 2026 202485
  1. Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults (2023)
    Ann R. Falsey, Kristi L. Williams et al. New England Journal of Medicine

Immediate Impact

7 by Nobel laureates 2 from Science/Nature 71 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
2024 Standout
2 intermediate papers

Works of Stephan Bart being referenced

Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial
2019
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant
2016

Author Peers

Author Last Decade Papers Cites
Stephan Bart 210 294 69 19 420
Joan R. Davies 149 221 58 25 432
Leigh A. Sawyer 244 124 80 14 414
Erin Sparrow 161 311 62 23 431
Cathy Maes 104 317 128 12 427
Yu Mao 190 386 71 10 496
Alexander Doroshenko 175 235 26 26 375
Taff Jones 154 255 148 20 390
M. A. Chernesky 143 181 26 15 404
D. Tien Nguyen 120 338 54 14 410
Amary Fall 300 264 20 45 459

All Works

Loading papers...

Rankless by CCL
2026